Kojie Pharmaceutical-B (02171) presented the research results of CT0596 and CT1190B at the EHA Annual Meeting in 2026.

Wisdom Financial APP News, Keji Pharmaceutical-B (02171) announced that the research results of CT0596 (a universal CAR-T cell product targeting BCMA) for the treatment of relapsed/refractory multiple myeloma (R/R MM) and plasma cell leukemia (PCL), as well as the research results of CT1190B (a universal CAR-T cell product targeting CD19/CD20) for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), have been presented in poster presentations at the 2026 European Hematology Association (EHA) annual meeting.